Heritage Way Advisors LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 0.8% during the second quarter, Holdings Channel reports. The firm owned 19,069 shares of the company’s stock after buying an additional 150 shares during the period. Johnson & Johnson makes up 2.2% of Heritage Way Advisors LLC’s investment portfolio, making the stock its 6th largest position. Heritage Way Advisors LLC’s holdings in Johnson & Johnson were worth $2,523,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Lenox Wealth Advisors Inc. raised its stake in shares of Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after buying an additional 6 shares during the period. Thomas J. Herzfeld Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $117,000. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after buying an additional 841 shares during the period. Ullmann Financial Group Inc. acquired a new stake in shares of Johnson & Johnson during the first quarter worth approximately $186,000. Finally, Taylor Wealth Management Partners raised its stake in shares of Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after buying an additional 250 shares during the period. Institutional investors and hedge funds own 66.06% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.12% during trading on Monday, hitting $133.02. The stock had a trading volume of 880,256 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The stock’s 50-day moving average price is $133.33 and its 200 day moving average price is $125.48. The firm has a market capitalization of $358.33 billion, a P/E ratio of 22.51 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same period last year, the firm earned $1.74 EPS. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a $0.84 dividend. The ex-dividend date is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

COPYRIGHT VIOLATION WARNING: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/07/heritage-way-advisors-llc-acquires-150-shares-of-johnson-johnson-jnj.html.

A number of analysts recently commented on the company. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Friday. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.90 price target on the stock. in a report on Monday, May 8th. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Wells Fargo & Company reiterated a “market perform” rating and set a $135.00 price target (up from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Finally, UBS AG reiterated a “buy” rating and set a $136.00 price target on shares of Johnson & Johnson in a report on Monday, May 15th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $133.72.

In related news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.